

Haematologica  
HAEMATOL/2018/212845  
Version 3

Thrombopoietin receptor agonists: Ten Years Later

Waleed Ghanima, Nichola Cooper, Francesco Rodeghiero, Bertrand Godeau, and James B. Bussel

Disclosures: This work have not been supported by a grant Individual disclosures: Waleed Ghanima reports grants and personal fees from Novartis, grants from Bayer, grants from Pfizer, grants from BMS, personal fees from Amgen, outside the submitted work. Nichola Cooper repots fees for advisory boards and educational events from Amgen, Novartis and Rigel outside the submitted work. Francesco Rodeghiero reports personal fees from Novartis, personal fees from UCB, personal fees from Argenx, personal fees from Amgen, outside the submitted work. Bertrand Godeau reports grants and personal fees from AMGEN, personal fees from Novartis, personal fees from LFB, grants from Roche, outside the submitted work. James Bussel reports grants and personal fees from Novartis, grants and personal fees from Amgen, grants and personal fees from Rigel, personal fees from Monenta, personal fees from Argenx, personal fees from UCB, personal fees from Dova outside the submitted work.

Contributions: All authors contributed to the literature review and writing of the manuscript.